Objective This systematic review aims to evaluate the benefit and side e□ect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.Methods All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.Results We included 22 randomized trials.Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.